# Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

> **NCT00441818** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tanox** · enrollment: 59 (estimated)

## Conditions studied

- Hodgkin's Lymphoma

## Interventions

- **DRUG:** TNX-650

## Key facts

- **NCT ID:** NCT00441818
- **Lead sponsor:** Tanox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2008-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441818, "Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00441818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*